BiotechTube

ALN-4324 + Placebo

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obese or Overweight Healthy Volunteers

Conditions

Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)

Trial Timeline

Mar 3, 2025 → Aug 31, 2027

NCT ID
NCT06845202

About ALN-4324 + Placebo

ALN-4324 + Placebo is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for Obese or Overweight Healthy Volunteers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06845202. Target conditions include Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM).

Hype Score Breakdown

Clinical
9
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07465224Phase 2Recruiting
NCT06845202Phase 1/2Recruiting

Competing Products

9 competing products in Obese or Overweight Healthy Volunteers

See all competitors
ProductCompanyStageHype Score
LorcaserinEisaiPhase 1
29
Bardoxolone methyl + PlaceboKyowa KirinPhase 1
29
LIK066 + PlaceboNovartisPhase 2
35
Investigational new drug company code: BGS649 + PlaceboNovartisPhase 2
27
Placebo + CT-388RochePhase 2
39
Growth hormone treatmentPfizerPre-clinical
26
BMS-963272 + PlaceboBristol Myers SquibbPhase 1
29
Aleniglipron + PlaceboStructure TherapeuticsPhase 2
36
CRB-913 + PlaceboCorbus PharmaceuticalsPhase 1
26